Ventures West contributes a wealth of resources to each of its venture capital investees.
With 5 professional technology investment managers, and one of the most productive Entrepreneur-In-Residence programs in Canada, the Ventures West team has over 100 years of technology venture investing and hands-on operating experience.
Ventures West has a unique set of capabilities - a long and successful track record in venture capital investing, management depth, extensive contacts in North American technology, financial, and venture capital industries, and the ability to form investor syndicates.
April 21, 2012
Presidio Pharmaceuticals Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV
April 19, 2012
Presidio Pharmaceuticals Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor
April 19, 2012
Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics
March 7, 2012
Silicor Materials, Formerly Calisolar, Announces Customer and Financing Partners for Major Manufacturing Expansion
